Abstract
Common radionuclides used for radiometabolic therapy include 131I, 153Sm, 89Sr, 223Ra, and 90Y. This chapter will focus on therapeutic radiopharmaceuticals employed for therapy of differentiated follicular thyroid carcinomas, for therapy of pheochromocytoma/paraganglioma/neuroblastomas, for bone pain palliation, for radioimmunotherapy of lymphomas, for peptide radioreceptor therapy of neuroendocrine tumors, and for intra-arterial radioembolization of hypervascularized tumors of the liver.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- CCK:
-
Cholecystokinin
- DIT:
-
Diiodotyrosine
- DOTA:
-
1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
- DOTANOC:
-
DOTA-1-Nal3-octreotide
- DOTATATE:
-
DOTA-D-Phe1-Tyr3-octreotate or DOTA-Tyr3-Thre8-octreotide
- DOTATOC:
-
DOTA-D-Phe1-Tyr3-octreotide
- EDTMP:
-
Ethylenediamine tetramethylene phosphoric acid
- GLP-1:
-
Glucagon-like peptide-1
- GRP:
-
Gastrin-releasing peptide
- Gy:
-
Gray
- HACA:
-
Human anti-chimeric antibody
- HAHA:
-
Human anti-human antibody
- HAMA:
-
Human anti-mouse antibody
- HEDP:
-
Hydro-ethylidene diphosphate
- Kev:
-
Kiloelectronvolt
- KI:
-
Potassium iodide
- LET:
-
Linear energy transfer
- MeV:
-
Megaelectronvolt
- MIBG:
-
Meta-iodobenzylguanidine
- MIT:
-
Monoiodotyrosine
- NET:
-
Neuroendocrine tumor
- NHL:
-
Non-Hodgkin’s lymphoma
- NIS:
-
Sodium-iodide symporter
- PRRT:
-
Peptide receptor radionuclide therapy
- PSMA:
-
Prostate specific membrane antigen
- RGD:
-
Tripeptide composed of l-arginine, glycine, and l-aspartic acid
- RIT:
-
Radioimmunotherapy
- RLT:
-
Radioligand therapy
- SPECT:
-
Single photon emission tomography
- SSTR:
-
Somatostatin receptors
- T3:
-
3,5,3′-Triiodothyronine
- T4:
-
3,5,3′,5′-Tetraiodothyronine
- TAT:
-
Target alpha therapy
- TSH:
-
Thyroid stimulating hormone
Suggested Readings
Alsultan AA, Braat AJAT, Smits MLJ, et al. Current status and future direction of hepatic radioembolisation. Clin Oncol. 2021;33:106–16.
Baum RP (Ed). Therapeutic nuclear medicine. New York: Springer; 2014.
Bodei L, Lam M, Chiesa C. EANM procedure guideline for treatment of refractory metastatic bone pain. Eur J Nucl Med Mol Imaging. 2008;35:1934–40.
Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800–16.
Dash A, Das T, Knapp FFR. Targeted radionuclide therapy of painful bone metastases: past developments, current status, recent advances and future directions. Curr Med Chem. 2020;27:3187–249.
Ell PJ, Gambhir SS (Eds). Nuclear medicine in clinical diagnosis and treatment. 3rd ed. New York: Churchill Livingston; 2004.
Fani M, Peitl PK, Velikyan I. Current status of radiopharmaceuticals for the theranostics of neuroendocrine neoplasms. Pharmaceuticals (Basel). 2017;10(1):30.
Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38:1393–406.
Giammarile F, Chiti A, Lassmann M, et al. EANM. EANM procedure guidelines for 131I-meta-iodobenzylguanidine (131I-mIBG) therapy. Eur J Nucl Med Mol Imaging. 2008;35:1039–47.
Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.
Herbert JC, Eckelman WC, Neumann RD (Eds). Nuclear medicine—diagnosis and therapy. New York: Thieme Medical Publishers; 1996.
Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, et al. Radiotheranostics: a roadmap for future development. Lancet Oncol. 2020;21:e146–56.
Hope TA, Abbott A, Colucci K, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177Lu-DOTATATE. J Nucl Med. 2019;60:937–43.
IAEA. Good practice for introducing radiopharmaceuticals for clinical use. Vienna: International Atomic Energy Agency (IAEA); 2015.
IAEA. Trends in radiopharmaceuticals (ISTR-2019). Vienna: International Atomic Energy Agency (IAEA); 2020.
Knapp FF, Dash A (Eds). Radiopharmaceuticals for therapy. New Delhi: Springer; 2016.
Knapp FF, Dash A. Radiopharmaceuticals for therapy. New Delhi: Springer; 2016.
Kowalsky RJ, Falen SW (Eds). Radiopharmaceuticals in nuclear pharmacy and nuclear medicine. 4rd ed. Washington, DC: American Pharmacists Association; 2020.
Kratochwil C, Afshar-Oromieh A, Kopka K, et al. Current status of prostate-specific membrane antigen targeting in nuclear medicine: clinical translation of chelator containing prostate-specific membrane antigen ligands into diagnostics and therapy for prostate cancer. Semin Nucl Med. 2016;46:405–18.
Kratochwil C, Fendler WP, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019;46:2536–44.
Langbein T, Weber WA, Eiber M. Future of theranostics: an outlook on precision oncology in nuclear medicine. J Nucl Med. 2019;60(Suppl 2):13S–9S.
Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59.
Martins CD, Kramer-Marek G, Oyen WJG. Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. Expert Opin Drug Deliv. 2018;15:185–96.
Owunwanne A, Patel M, Sadek S (Eds). The handbook of radiopharmaceuticals. New York: Springer; 1995.
Poeppel TD, Handkiewicz-Junak D, Andreeff M, et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45:824–45.
Prince JF, Van Den Bosch MAAJ, Nijsen JFW, et al. Efficacy of radioembolization with 166Ho-microspheres in salvage patients with liver metastases: a phase 2 study. J Nucl Med. 2018;59:582–8.
Schwochau K (Ed). Technetium: chemistry and radiopharmaceuticals. Hoboken: Wiley; 2000.
Sgouros G, Bodei L, McDevitt MR, et al. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020;19:589–608.
Silberstein EB, Alavi A, Balon HR, et al. The SNM practice guideline for therapy of thyroid disease with 131I 3.0*. J Nucl Med. 2012;53:1633–51.
St James S, Bednarz B, Benedict S, et al. Current status of radiopharmaceutical therapy. Int J Radiat Oncol Biol Phys. 2021;109:891–901.
Stokkel MP, Handkiewicz Junak D, Lassmann M, et al. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37:2218–28.
Tennvall J, Fischer M, Bischof Delaloye A, et al. EANM procedure guideline for radioimmunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). Eur J Nucl Med Mol Imaging. 2007;34:616–22.
Theobald T (Ed). Sampson’s texbook of radiopharmacy. 4th ed. London: Pharmaceutical Press; 2010.
Volterrani D, Erba PA, Carrió I, Strauss HW, Mariani G (Eds). Textbook of nuclear medicine—methodology and clinical applications. Cham: Springer Nature Switzerland AG; 2019.
Welch MJ, Redvanly CS (Eds). Handbook of radiopharmaceuticals: radiochemistry and applications. Hoboken: Wiley; 2003.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Orsini, F., Mazzarri, S., Puta, E., Guidoccio, F., Lorenzoni, A., Mariani, G. (2022). Radiopharmaceuticals for Therapy. In: Volterrani, D., Erba, P.A., Strauss, H.W., Mariani, G., Larson, S.M. (eds) Nuclear Oncology. Springer, Cham. https://doi.org/10.1007/978-3-031-05494-5_34
Download citation
DOI: https://doi.org/10.1007/978-3-031-05494-5_34
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-05493-8
Online ISBN: 978-3-031-05494-5
eBook Packages: MedicineReference Module Medicine